252-254 Hf, Cm, Transplant Flashcards

1
Q

MCC HFpEF

A

Htn 75%

Cad 60-75%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Normal jvp height

A

8cm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Normal pulmo artery pressure

A

15mmHg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Dilated cardiomyopathy tx

A
  • almost 1/2 shows spontaneous recovery
  • bb, raas inhibitors
  • cardiac resynchronization pacing: in whom lbbb precedes clinical hf by many years
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Dallas criteria for myocarditis

A
  • lymphocytic infiltrate with evidence of myocarditis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Mcc myocarditis

A

Infective

  • viral
  • t cruzi: most common infective caus eof ccardiomyopathy and 3rd mc parasitic infxn in the world
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Viral myocarditis

A

No effective tx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Viral myocarditis

A

No effective tx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Chagas disease phases, dx, tx

A
  • acute: nonspecific
  • chronic: progresses over 10-30yrs, gi and cardiac (conduction system abnormalities)
  • dx: at least 2 serologic positive test
  • tx: supportive, benznidazole/nifurtimox unclear if can prevent disease progression
  • <30% 5yr survival when onset of clinical hf
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

African trypanosomiasis

A
  • tse tse fly
  • western: t. Brucei gambiense, slow silent progression
  • eastern: t. Brucei rhodesiende, rapid progression
  • antiparasitic tx of limited efficacy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Bacterial infection myocarditis

A

Diphtheria - affects 1/2 of cases and is mcc death, antitoxin priority over antibiotic
Clostridium - abscess
Strep (GAS) - rheumatic fever
Tb
Tropheryma whipplei - tx antitb meds, high recurrence
Lyme disease: resolves in 1-2 wks of tx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Sarcoidosis

A
  • right ventricular affectation
  • dx: pet scan, biopsy of mediastinal ln (partchy cardiac involvement likely to be missed with cardiac biopsy)
  • tx: glucocorticoids, immunosuppression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Giant cell myocarditis

A
  • granulomatous lesions surrounded by extensive inflammatory infiltrate unlikely to be missed on myocardial biopsy
  • tx: glucocort + immunosuppression
  • rapid detoriation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Eosinophilic myocarditis

A
  • churg strauss
  • malignancy
  • hypersensitivity: antibiotics, thiazides, methyldopa, anticonvulsants, indomethacin
  • glucocort and withdrawal of offending agent
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Peripartum cardiomyopathy onset and risk factors

A

Last trimester and first 6mos postpartum

- age, parity, twin, mulnutrition, use of tocolytic, preecclampsia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Mcc toxic cardiomyopathy

A
  • Alcohol
  • Contribute to >10% of hf
  • 5-6drinks (4oz of pure alcohol) daily for 5-10yrs
  • improvement in 3-6mos of cessation
  • tx: neurohormonal antagonist and diuretics
17
Q

Chemotx cardiomyopathy

A
  1. Anthracyclines
    - vacuolar degeneration and myofibrillar loss
    - occur late after exposure
    - tx: neurohormonal antagonist and bb
  2. Trastuzumab
    - less than anthracyclines
    - reversible
  3. 5fu, cisplatin, alkylators
    - coronary vasospasm
  4. Carfilzumab>bortezomib
  5. Ipilimumab, nivolumab - fulminant myocarditis when combined
  6. Vegf inhibitors
18
Q

Beri beri

A

High output cardiac failure

19
Q

Left ventricular noncompaction findings

A
  • taz gene (tafazzin)

- multiple trabeculations in the lv distal to the papillary muscles

20
Q

Left ventricular noncompaction triad

A
  1. Arrhythmia
  2. Heart failure
  3. Emboli
    Tx: anticoag, icd, neurohormonal antagonist
21
Q

Takotsubo cardiomyopathy

A
  • apical ballooning syndrome, global ventricular dilation with basal contractikn
  • ecg: mimic mi
  • intense sympathetic activation
  • no tx supportive (bb, nitrates for pulmo edema,mgso4 for long qt arrhythmia), prognosis generally good
22
Q

Fabry disease biopsy findings

A

Diagnostic vesicles containing concentric lamellar figures

23
Q

Danon’s disease

A

Lamp2 gene: x linked

Cardiomyopathy, mental retardation, skeletal myopathy

24
Q

Restrictive carduomyopathy amyloidosis gene

A
  • Transthyretin V122I chromosome 13
  • 50%risk of hf
  • Refractile brightness on 2d echo
  • amyloid fibrils infiltrate the conduction system and coronary arteries
  • if primary amyloid tx: bortezomib
25
Q

Loeflers endocarditis

A

Eosinophilic injury to the myocardium
Dense fibrotic layer obliterate the ventricular apices
Tx glucocorticoids

26
Q

Hocm 80% of mutations are due to

A
  • myh7
  • mybpc3: average onset 40y/o
  • obstruction + in 30%, provoked by exercise in another 30%
    Tx: bb, ccb, disopyramide (antiarrhythmic with potent negative inotropic properties)
27
Q

Cardiac transplant cold ischemia time

A

4hrs

28
Q

Cardiac conditioning hormone used

A

Thyroid

29
Q

Most common heart transplant surgery

A
  • bicaval orthotopic cardiac transplant

- denervated: if with bradycardia cannot be treated with atropine need to give isoproterenol

30
Q

Triple drug immunosuppresion for cardiac transplantation

A
  • calcineurin inhibitor (cyclosporine, tacrolimus)
  • glucocorticoids
  • antiproliferative immunosuppression (azathioprine, mycophenolate mofetil, sirolimus, everolimus)
31
Q

Assist devices

A
  • heart mate II:pulsatile, intrathoracic+ abdominal, no intrinsic pulse
  • heart ware: continuous centrifugal flow
  • heart mate III: continuous, fully intrathoracic magnetically levitated, with intrinsic pulse
    (MOMENTUM trial)
  • syncardia: biventricular
32
Q

Reductions in mortality
Acei
Bb
Spironolactone

A

Ace inhibitor 23%
Beta blocker 35%
Spironolactone 30%